Daiichi Sankyo says Sun Pharma to buy Indian unit Ranbaxy
TOKYO (Reuters) - Japan's Daiichi Sankyo Co Ltd (4568.T) said on Monday Sun Pharmaceutical Industries Ltd (SUN.NS) will buy its Indian unit Ranbaxy Laboratories Ltd (RANB.NS), creating the world's fifth-largest speciality generics company.
Daiichi Sankyo said in a statement that it agrees to vote its shares in Ranbaxy in favour of the acquisition through a share swap.
It said Ranbaxy shareholders will get 0.8 Sun Pharma shares for each Ranbaxy share. The merged company will also become the largest drug firm in India.
(Reporting by Dominic Lau; Editing by Stephen Coates)
- Tweet this
- Share this
- Digg this
- Tesco accounting black hole deepens, chairman to step down |
- UPDATE 2-Tennis-WTA Finals women's singles round robin results
- Britain slams EU budget demand, others see 'molehills'
- Hungary plans new tax on Internet traffic, public calls for rally
- Doctor who worked in Africa first Ebola case in New York City |